CYP2F1 Enzyme: Drug Target Or Biomarker for Cancer? (G1572)

Target Name: CYP2F1

NCBI ID: G1572

CYP2F1

CYP2F1 Enzyme: Drug Target Or Biomarker for Cancer?

CYP2F1, also known as microsomal monooxygenase, is a enzyme located in the mitochondria that is involved in the metabolism of various drugs. This enzyme plays a crucial role in the metabolism of many drugs, including many anti-cancer drugs, which means that it can be a valuable drug target or biomarker for cancer treatment.

The CYP2F1 enzyme is a monooxygenase, which means that it produces reactive oxygen species (ROS) from oxygen. These ROS can interact with other molecules and cause damage to cells, which can lead to the development of cancer. The CYP2F1 enzyme is also known for its role in the metabolism of drugs that are used to treat various diseases, such as cardiovascular disease, diabetes, and neurodegenerative disorders.

One of the main functions of the CYP2F1 enzyme is to metabolize drugs that are used to treat cancer. Many anti-cancer drugs work by inhibiting the activity of the CYP2F1 enzyme, which can lead to the reduced production of these drugs and an increase in their toxicity. For example, the drug irinotecan is used to treat colorectal cancer, and it works by inhibiting the activity of the CYP2F1 enzyme. When irinotecan is administered to patients, it can cause a severe side effect known as myelosuppression, which can lead to a low white blood cell count.

Another function of the CYP2F1 enzyme is its role in the metabolism of drugs used to treat cardiovascular disease. The CYP2F1 enzyme is also involved in the metabolism of many drugs used to treat diabetes, such as metformin and prediabetes. These drugs work by modulating the activity of the CYP2F1 enzyme and improving insulin sensitivity in the body.

In addition to its role in the metabolism of drugs used to treat cancer and cardiovascular disease, the CYP2F1 enzyme is also involved in the metabolism of drugs used to treat neurodegenerative disorders. The CYP2F1 enzyme is used to metabolize the drug donepezil, which is used to treat the symptoms of Alzheimer's disease.

The CYP2F1 enzyme is also a potential biomarker for cancer. The expression of the CYP2F1 enzyme has been shown to be elevated in the bodies of patients with various types of cancer, including breast, lung, and ovarian cancer. This suggests that the CYP2F1 enzyme may be a useful biomarker for the diagnosis and monitoring of cancer.

In conclusion, the CYP2F1 enzyme is a microsomal monooxygenase that is involved in the metabolism of various drugs. It plays a crucial role in the treatment of cancer, cardiovascular disease, and neurodegenerative disorders. The CYP2F1 enzyme is also a potential biomarker for cancer, which can be used to diagnose and monitor the progression of cancer. Further research is needed to fully understand the role of the CYP2F1 enzyme in the treatment of cancer and to develop new treatments based on this understanding.

Protein Name: Cytochrome P450 Family 2 Subfamily F Member 1

Functions: May be involved in the metabolism of various pneumotoxicants including naphthalene. Is able to dealkylate ethoxycoumarin, propoxycoumarin, and pentoxyresorufin but possesses no activity toward ethoxyresorufin and only trace dearylation activity toward benzyloxyresorufin. Bioactivates 3-methylindole (3MI) by dehydrogenation to the putative electrophile 3-methylene-indolenine

The "CYP2F1 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about CYP2F1 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets